ClinicalTrials.gg
RecruitingNCT07746544Updated Sep 2, 2026

Study of Secutrelvir in Participants With COVID-19

A Phase 3 interventional study of Secutrelvir and Placebo in COVID-19, sponsored by Shionogi. Recruiting at 1 site in Japan. Open to participants aged 12 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
12 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.

Planned enrollment
21st of 59
1,200 · median 602
Started
2026
with 2 others
Phase 3
34 of 75
8 open now
Primary completion
2027-07
later than 4 of 10 live
Registered
73rd of 75
by date
Lead sponsor
5 of 75
Shionogi

Among the 75 studies in COVID-19 with a site in Japan, this one is the 21st largest by planned enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2026, is one of 34 in phase 3, reaches primary completion later than 4 of the 10 other live ones, and was the 73rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in COVID-19 with a site in Japan, or all of them as a file.
02

Study summary

The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • S-892216
  • SARS-CoV-2
  • Mpro
  • Main Protease
  • Nonstructural Protein 5
  • nsp5
04

Who can participate

Ages eligible
12 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must be 12 to \< 18 years of age (where permitted by local regulation) with a body weight ≥ 40 kilograms (kg), or ≥ 18 and \< 75 years of age regardless of body weight, at the time of signing the form (ICF).
  • Must have ≥ 1 of the protocol-defined COVID-19 symptoms of moderate or severe, present within 24 hours prior to randomization.
  • Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by any SARS-CoV-2 test, collected ≤ 48 hours prior to randomization.
  • Must be randomized within 48 hours of COVID-19 symptom onset, defined as the time when the first COVID-19 symptom occurs.
  • Agrees not to participate in another clinical study for the treatment of COVID-19 until completion of the study.

Key Exclusion Criteria:

  • Current need or anticipated need for hospitalization within 24 hours, due to signs of severe COVID-19 illness or due to other medical conditions requiring hospitalization in the opinion of the site investigator.
  • Documented respiratory infection (for example, influenza, respiratory syncytial virus infection) other than COVID 19 within 14 days prior to the screening visit.
  • Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy).
  • Suspected or confirmed COVID-19 outside of the current episode within 3 months of randomization.
  • Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the intervention.
  • Ongoing long COVID or postacute sequelae of COVID (PASC) diagnosis.
  • Current severely conditions.
  • Received or expected to receive any other COVID-19-specific therapies.
  • Have previously received secutrelvir.
  • Exposed to an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the screening visit.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Secutrelvir

    Participants will receive secutrelvir administered orally.

    Drug: Secutrelvir

  • Placebo comparator
    Placebo

    Participants will receive placebo administered orally.

    Drug: Placebo

Interventions

  • DrugSecutrelvir

    Secutrelvir will be administered orally as a tablet.

    Also known as: S-892216

  • DrugPlacebo

    Placebo will be administered orally as a tablet.

06

What researchers measure

Primary outcomes

  1. Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 21

Secondary outcomes

  1. Time to Sustained Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 28

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 28

  2. Time to Sustained Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 21

  3. Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Symptoms Through Day 28

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 28

  4. Time to First Alleviation of 14 Protocol-defined Symptoms of COVID-19 Through Day 21

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 21

  5. Time to Sustained Alleviation of 14 Protocol-defined Symptoms of COVID-19 Through Day 21

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 21

  6. Area Under The Curve (AUC) of Change From Baseline in Protocol-defined 14 COVID 19 Symptoms Total Score at Day 8

    Time frame: Baseline, Day 8

  7. Time to First Resolution of Fever Based on Body Temperature

    Symptoms will be assessed by the investigator via a participant daily electronic diary.

    Time frame: Baseline through Day 28

  8. Time to Sustained Resolution of Fever Based on Body Temperature

    Symptoms will be assessed by the investigator via a participant daily electronic diary

    Time frame: Baseline through Day 28

  9. Change From Baseline in SARS-CoV-2 Viral RNA Level

    Time frame: Baseline through Day 28

  10. Percentage of Participants With All-cause Hospitalization

    Time frame: Baseline through Day 21

  11. Percentage of Participants With All-cause Death

    Time frame: Baseline through Day 21

  12. Plasma Concentration of Secutrelvir and Its Metabolites

    Time frame: Days 4 and 8

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline through Day 28

07

Study locations

1 of 1 sites recruiting
  • Japanese Site 1
    Multiple Locations, Japan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Aug 5, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07746544
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Aug 5, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
Contact
Shionogiclintrials-admin@shionogi.co.jp
1-800-849-9707

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion